BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy
Autor: | Kohei Shigeta, Ryo Seishima, Yusuke Asada, Yuko Kitagawa, Masashi Tsuruta, Shingo Akimoto, Koji Okabayashi, Osamu Itano, Takashi Ishida, Hirotoshi Hasegawa, Kaoru Koishikawa, Takehiro Shimada, Hirofumi Suzumura |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male Cancer Research Chromosomal Proteins Non-Histone Colorectal cancer Malignancy Gentamicin protection assay Cell Movement Prostate medicine Humans Neoplasm Invasiveness Transcription factor Aged Aged 80 and over business.industry General Medicine Transfection Middle Aged medicine.disease Progression-Free Survival digestive system diseases DNA-Binding Proteins Gene Expression Regulation Neoplastic Blot medicine.anatomical_structure Oncology Cancer research Female Neoplasm Recurrence Local Colorectal Neoplasms Ovarian cancer business HT29 Cells Signal Transduction |
Zdroj: | Anticancer Research. 41:5445-5452 |
ISSN: | 1791-7530 0250-7005 |
Popis: | Background/aim The role of brahma-related gene 1 (BRG1)-associated factor 57 (BAF57), a transcription factor, has been determined in prostate, breast, and ovarian cancer. However, the relationship between BAF57 and colorectal cancer (CRC) is obscure. Thus, we examined the functional correlation between BAF57 expression and oncological malignancy in CRC in vitro. Materials and methods BAF57 expression in WiDr and HT29 CRC cell lines and clinical specimens from CRC patients was analysed by western blotting and/or RT-PCR. BAF57 expression was down-regulated in WiDr cells through siRNA transfection. An invasion assay was also performed to assess malignancy. Results BAF57 was expressed in both human CRC cell lines. Overall survival and recurrence-free survival rates were significantly reduced in high BAF57-expressing specimens. BAF57 expression was an independent predictive factor for long-term survival. Conclusion BAF57 correlates with oncological malignancy and may be a novel therapeutic target in CRC. |
Databáze: | OpenAIRE |
Externí odkaz: |